NASDAQ : RGNX
REGENXBIO Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 7.41 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 489.16M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 475.29M |
| Enterprise Value | 620.24M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 66.01M |
| Shares Outstanding | 66.01M |
| Shares Change (YoY) | +2.03% |
| Shares Change (QoQ) | +1.12% |
| Owned by Insiders (%) | 6.69% |
| Owned by Institutions (%) | 59.30% |
| Float | 57.23M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.72 |
| Forward PS | 6.80 |
| PB Ratio | 5.43 |
| P/TBV Ratio | 6.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 3.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.86 |
| Quick Ratio | 2.70 |
| Debt / Equity | 3.49 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.91 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -137.63% |
| Return on Assets (ROA) | -21.20% |
| Return on Invested Capital (ROIC) | -97.79% |
| Return on Capital Employed (ROCE) | -54.00% |
| Weighted Average Cost of Capital (WACC) | 11.42% |
| Revenue Per Employee | $470,302 |
| Profits Per Employee | -$529,466 |
| Employee Count | 371 |
| Asset Turnover | 0.36 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.13 |
| 52-Week Price Change | -43.93% |
| 50-Day Moving Average | 7.98 |
| 200-Day Moving Average | 9.17 |
| Relative Strength Index (RSI) | 46.42 |
| Average Volume (20 Days) | 1,383,203 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 10.04M |
| Short Previous Month | 9.61M |
| Short % of Shares Out | 15.21% |
| Short % of Float | 17.55% |
| Short Ratio (days to cover) | 6.44 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 174.48M |
| Gross Profit | -78.42M |
| Operating Income | -164.15M |
| Pretax Income | -196.43M |
| Net Income | -196.43M |
| EBITDA | -148.78M |
| EBIT | -164.15M |
| Loss Per Share | -$3.77 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 105.52M |
| Total Debt | 250.46M |
| Net Cash | -144.95M |
| Net Cash Per Share | -$2.20 |
| Equity (Book Value) | 71.77M |
| Book Value Per Share | 1.32 |
| Working Capital | 153.54M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -246.67M |
| Capital Expenditures | -2.99M |
| Depreciation & Amortization | 15.37M |
| Net Borrowing | n/a |
| Free Cash Flow | -249.67M |
| FCF Per Share | -$3.78 |
Margins
| Measure | Value |
|---|
| Gross Margin | -44.95% |
| Operating Margin | -94.08% |
| Pretax Margin | -112.58% |
| Profit Margin | -112.58% |
| EBITDA Margin | -85.27% |
| EBIT Margin | -94.08% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.03% |
| Shareholder Yield | -2.03% |
| Earnings Yield | -52.29% |
| FCF Yield | -52.53% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $24.55 |
| Price Target Difference | 240.97% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | 26.20% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -3.82 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |